Tegafur-uracil plus gemcitabine combination chemotherapy in patients with advanced non-small cell lung cancer previously treated with platinum

Takashi Seto, Takeharu Yamanaka, Makiko Nakano, Mayuko Ota, Riichiroh Maruyama, Tatsuro Okamoto, Hiroshi Wataya, Kazutsugu Uematsu, Nobuhiko Seki, Kenji Eguchi, Hiroshi Semba, Yukito Ichinose

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

BACKGROUND: An open-label, single-arm prospective study was conducted to evaluate the efficacy and toxicity of the combination of gemcitabine and tegafur-uracil (UFT) in patients with advanced nonsmall-cell lung cancer (NSCLC) after the failure of previous platinum-containing regimens. PATIENTS AND METHODS: Patients with advanced NSCLC received 200 mg/m of UFT twice daily from day 1 through 14 plus 900 mg/m of gemcitabine per day via intravenous injection on days 8 and 15. This regimen was repeated every 3 or 4 weeks. RESULTS: A total of 40 patients were enrolled. Eleven patients (28%; 95% confidence interval [CI], 15-44%) achieved a partial response. The median progression-free survival, median overall survival, and 1-year survival rate were 4.0 months (95% CI, 3.3-6.7 months), 12.6 months (95% CI, 7.0-22.3 months), and 51% (95% CI, 33-66%), respectively. The most common grade 3 or 4 toxicity was neutropenia (38%; 95% CI, 23-54%) and the rate of grade 3 or 4 nonhematologic toxicity remained at less than 5%. A multivariate Cox model showed that adenocarcinoma, nonsmoking history, and good performance status predicted better survival. CONCLUSIONS: Combination chemotherapy with UFT and gemcitabine showed a promising effectiveness and acceptable toxicity for patients with platinum-resistant NSCLC.

Original languageEnglish
Pages (from-to)637-642
Number of pages6
JournalJournal of Thoracic Oncology
Volume3
Issue number6
DOIs
Publication statusPublished - 2008 Jun

    Fingerprint

Keywords

  • Adenocarcinoma
  • Advanced nonsmall-cell lung cancer
  • Gemcitabine
  • Nonsmoking
  • Second-line chemotherapy
  • Tegafur-uracil

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Seto, T., Yamanaka, T., Nakano, M., Ota, M., Maruyama, R., Okamoto, T., Wataya, H., Uematsu, K., Seki, N., Eguchi, K., Semba, H., & Ichinose, Y. (2008). Tegafur-uracil plus gemcitabine combination chemotherapy in patients with advanced non-small cell lung cancer previously treated with platinum. Journal of Thoracic Oncology, 3(6), 637-642. https://doi.org/10.1097/JTO.0b013e318174e070